Sanofi-aventis, Innogenetics, and Inserm to collaborate on Alzheimer's disease
The present agreement is built on intellectual property and a research collaboration between Innogenetics and Inserm-Lille (U-422) on the development of new diagnostic tools for Alzheimer's disease (AD) dating back from 2002. The results of the collaboration shall allow to study the role of specific forms of the key Alzheimer protein amyloid beta, and related technology, as targets for new therapeutic avenues for AD. Based on the technology and products provided by Innogenetics and Inserm, Sanofi will evaluate different products against diverse forms of the beta protein in a passive immunization program. In return for providing Sanofi-aventis access to their technology and services, Innogenetics and Inserm-Transfert will receive upfront and research fees.
In the event Sanofi-aventis exercises its license option, Innogenetics and Inserm-Transfert will be entitled to milestone payments and royalties on future sales of therapeutic products resulting from this collaboration.
Financial terms of the agreement were not disclosed.
Other news from the department science
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.